



Multiple  
Sclerosis  
Society of  
Canada

Société  
canadienne  
de la sclérose  
en plaques



175 Bloor Street East  
Suite 700, North Tower  
Toronto, Ontario M4W 3R8  
Telephone: (416) 922-6065  
Fax: (416) 922-7538  
[www.mssociety.ca](http://www.mssociety.ca)

## Medical Update Memo

February 24, 2006

### **Clinical trial underway for new monoclonal antibody daclizumab**

An international multi-centre clinical trial is underway to test the safety and effectiveness of daclizumab compared with inactive placebo. Investigators - including study sites in Canada - are enrolling 270 participants who meet the study criteria, which includes currently taking one of the beta interferon therapies.

About daclizumab: This agent is a laboratory-created monoclonal antibody that blocks the activity of a key immune activator in MS. A small study involving 19 people with relapsing-remitting or secondary-progressive MS conducted by Dr. John Rose and colleagues at the University of Utah found the therapy resulted in stability (nine participants) or improvement (10).

Clinical trial criteria: To be eligible for the study, participants must be 18-55 years old, have definite MS, be taking one of the beta interferon therapies and have experienced a relapse or MRI-detected disease activity within nine months prior to screening.

For more information, call the study enrolment centre at 1 800 772-0482 (English only) or go to the study website: [www.choicestudy.com](http://www.choicestudy.com) (English only)

**ASK MS Information System Code: 1.4.1.12.2.w**

National Research Department  
National Communications & Government Relations Department

Disponible en français